A phase II safety and immunogenicity trial of live recombinant canarypox ALVAC-HIV vCP205 [HIV vaccine vCP205] with or without HIV-1 SF-2 RGP120 [HIV gp120 vaccine] in HIV-1 uninfected adult volunteers.

Trial Profile

A phase II safety and immunogenicity trial of live recombinant canarypox ALVAC-HIV vCP205 [HIV vaccine vCP205] with or without HIV-1 SF-2 RGP120 [HIV gp120 vaccine] in HIV-1 uninfected adult volunteers.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs HIV gp120 vaccine (Primary) ; HIV vaccine vCP205 (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 28 Sep 2008 Actual end date (Jan 2000) added as reported by CT.gov
    • 28 Sep 2008 Actual start date (May 1997) added as reported by CT.gov
    • 28 Sep 2008 Status changed from active, no longer recruiting to completed as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top